Encure Biotherapeutics
Encure Biotherapeutics
  • Home
  • Platforms
    • Encure Bio-SWATI-AI
    • eSENTs
  • Clinical Pipelines
    • Encure Bio CVD pipelines
  • Team
    • Executive Team
  • Collaborations
    • Partners
  • News
    • Earlier study -MMRI
  • Publications
    • eSENTs technology
    • RNA Delivery
    • Bioinspired nanomaterials
    • AntiCCR2 Nanotherapeutics
    • Nano‑Immune Engineering
    • Stemcell -Biomimcry
    • Patents
    • Lipid nanoengineering
  • More
    • Home
    • Platforms
      • Encure Bio-SWATI-AI
      • eSENTs
    • Clinical Pipelines
      • Encure Bio CVD pipelines
    • Team
      • Executive Team
    • Collaborations
      • Partners
    • News
      • Earlier study -MMRI
    • Publications
      • eSENTs technology
      • RNA Delivery
      • Bioinspired nanomaterials
      • AntiCCR2 Nanotherapeutics
      • Nano‑Immune Engineering
      • Stemcell -Biomimcry
      • Patents
      • Lipid nanoengineering
  • Home
  • Platforms
    • Encure Bio-SWATI-AI
    • eSENTs
  • Clinical Pipelines
    • Encure Bio CVD pipelines
  • Team
    • Executive Team
  • Collaborations
    • Partners
  • News
    • Earlier study -MMRI
  • Publications
    • eSENTs technology
    • RNA Delivery
    • Bioinspired nanomaterials
    • AntiCCR2 Nanotherapeutics
    • Nano‑Immune Engineering
    • Stemcell -Biomimcry
    • Patents
    • Lipid nanoengineering

Nano‑Engineered Immunotherapy for Cardiovascular Diseases

Encure Bio is advancing eSENTs technology with AI‑enhanced nanoengineering to develop next‑generatio

Encure Bio is advancing eSENTs (engineered Senescent Erythrocyte‑like NanoTherapeutics) using SWATI‑AI to accelerate AI‑enhanced nano‑engineered immunotherapy for cardiovascular diseases 

Copyright © 2026 Encure Bio - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept